/
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
Black Diamond Therapeutics (BDTX) generated about $0.00 in revenue and -$43 million in net income (a 32.0% net margin) over the trailing twelve months. Figures are from SEC filings; this is analysis, not investment advice.
Black Diamond Therapeutics generated about $0.00 in revenue over the trailing twelve months. Revenue is the top line, before any costs; what matters for value is how much of it survives to free cash flow. The full income statement, balance sheet and cash-flow statement are on this tab.
Black Diamond Therapeutics reported about -$43 million in net loss over the trailing twelve months, a net margin of roughly 32.0%. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.
Black Diamond Therapeutics runs an operating margin of about 17.9%, a net margin of about 32.0%. Margins show how much of each sales dollar a company keeps at each stage. Stable or rising margins usually signal pricing power and cost discipline; falling margins are worth investigating. See the multi-year trend on this tab.
SourceFinancial statements computed from the 10-Q filed 7 May 2026, covering the period ending 31 Mar 2026, as reported to the SEC. Data last refreshed 8 May 2026. How this is calculated.
Fiscal year ends Dec.